Source: Solid phase chemical synthesis

一、Product Introduction

Tilposide is a novel dual receptor agonist of glucagon like peptide-1 receptor (GLP-1) and glucose dependent insulinotropic peptide (GIP), administered once a week. GLP-1 and GIP both belong to enterotropin, which is a peptide secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing hypoglycemic effects. It can also delay gastric emptying and inhibit appetite, thereby controlling weight; The latter has functions such as inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the action of GLP-1 receptor agonists.

Structural formula:

二、Product features

三、Product advantages

1、Production form: fully synthetic, significantly reducing body weight, with good GLP-1 agonist activity and GIP receptor agonist activity

2、Capacity: 500L reactor with an annual output of 40kg

3、Technical support: stability research and support for DMF application

四、 Related products

Telposide side chains, Smegglutide, Liraglutide